CDx Diagnostics

Suffern, United States Founded: 1997 • Age: 29 yrs Acquired By Galen Partners
AI-based platform is utilized to detect precancerous tissues in biopsies.

About CDx Diagnostics

CDx Diagnostics is a Healthcare company based in Suffern (United States) founded in 1997 by Mark Rutenberg, and was acquired by Galen Partners in July 2017. AI-based platform is utilized to detect precancerous tissues in biopsies. It operates in the Healthcare and Technology sectors. CDx Diagnostics has raised $16.04 million across 2 funding rounds from investors including Galen Partners. CDx Diagnostics offers products and services including WATS 3D, OralCDx, and EndoCDx. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.

Company details

CDx Diagnostics was founded in 1997 and is headquartered in Suffern, United States. The company operates in the healthcare diagnostics sector, focusing on AI-driven technologies for early detection of precancerous conditions. Proprietary WATS3D biopsy platform is employed to identify tissue changes. Key products include OralCDx, a non-invasive oral brush biopsy system, and EndoCDx, a transepithelial laryngeal brush biopsy tool, supporting clinical assessments in oncology-related fields.

Key Metrics

Products & Services of CDx Diagnostics

CDx Diagnostics offers a comprehensive portfolio of products and services, including WATS 3D, OralCDx, and EndoCDx.

WATS 3D
Diagnostic Platform

AI-enabled tool for early detection of precancerous cells in esophagus.

OralCDx
Diagnostic Service

Platform for oral cancer prevention through advanced tissue analysis.

EndoCDx
Diagnostic Tool

Technology for detecting dysplasia in endoscopic procedures.

Apps and channels of CDx Diagnostics

its YouTube channel WATS3D has 7 subscribers and 11 videos.

WATS3D
YouTube 7 subscribers 11 videos Science & Technology
Open channel

Videos from CDx Diagnostics

The most watched videos on CDx Diagnostics's YouTube channel, WATS3D (7 subscribers). Click a video to play it here.

WATS3D Professional Overview Video
386 views
WATS Presentation at Epcot During ACG2017
99 views
EndoscopyNow Webinar - WATS3D for Barrett's Screening and Surveillance
88 views
Newly Published Data in GIE demonstrates the effectiveness of WATS3D vs the random Seattle protocol
47 views

More on WATS3D.

Funding Insights of CDx Diagnostics

CDx Diagnostics has successfully raised a total of $16.04M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $16.04M
  • Total Rounds 2
  • Last Round Series A — $5M
  • First Round $11.04M

    (Dec 2019)

All 2 funding rounds of CDx Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2020$5MSeries A––
–
Dec 2019$11.04MSeries A––
–
Valuation history

1 investors in total: 1 institutional.

Investors in CDx Diagnostics

CDx Diagnostics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Galen Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
PE firm investing in the US
galen.comStamford, United States
Premium access

Investor details for CDx Diagnostics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of CDx Diagnostics

22 people are tracked at CDx Diagnostics (6 in leadership, 4 in board & advisors, 12 in team).

NameRoleGroup
Mark Rutenberg
FounderLeadership
Tom Bartel
Executive Vice President Of SalesLeadership
Bonnie Pirtz
Senior Vice President, Market Access & ReimbursementLeadership
Robert Tjon
VP of EngineeringLeadership
Patricia Romano
Laboratory DirectorLeadership
Karen Hoffman
Director Of ResearchLeadership
Thomas A. Bologna
ChairmanBoard & advisors
John Watts
DirectorBoard & advisors
David Jahns
DirectorBoard & advisors
Michael D. Bacon
DirectorBoard & advisors
Amanda Perello
Senior Manager, IT Applications ManagementTeam
Jonathan Justin
Talent Acquisition LeadTeam
Roger O'Sullivan
General Counsel, Corporate Secretary, Compliance OfficerTeam
Ramesh Ramasamy
SVP, TechnologyTeam
Deborah Sherman
Senior AccountantTeam
Samantha Hippler
Client Services Team LeadTeam
Sheila Mosley
Laboratory Operations ManagerTeam
Marisol Padilla
Data Applications SpecialistTeam
Daniela Ducasse
Senior Credentialing SpecialistTeam
Stephen Frist M.D.
Consultant Research Pathologist - Computer Assisted Surgical Pathology And CytologyTeam

2 more people are available in the full profile.

Premium access

Complete people profiles for CDx Diagnostics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of CDx Diagnostics

4 dated milestones of CDx Diagnostics across 23 years, from founding to its latest funding, stage changes and deals.

  1. Founded CDx Diagnostics is founded.
  2. Exit Acquired by Galen Partners.
  3. Funding First funding round of $11.0M.
  4. Funding Latest funding round, Series A, of $5.0M.

Competitors of CDx Diagnostics

CDx Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
denalitherapeutics.com2015San Francisco, United States$347M377
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
poseida.com2015San Diego, United States$323.78M259
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
cernostics.com2008Pittsburgh, United States$14.18M16
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
Premium access

Detailed competitors of CDx Diagnostics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of CDx Diagnostics

The website of CDx Diagnostics (cdxdiagnostics.com) receives about 2.6K visits a month.

  • Monthly visits
    2.6K

    ▼ 15.9% vs previous month

Top companies in Clinical Genomics

3 companies that operate in the same segment as CDx Diagnostics (Clinical Genomics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
2013Seattle, Washington, United StatesUSD 316.67 M520
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cdx Diagnostics

Premium access

Complete news archive for CDx Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CDx Diagnostics

CDx Diagnostics was founded in 1997 and raised its 1st funding round 22 years after it was founded.

CDx Diagnostics is headquartered in Suffern, United States. It is registered at Suffern, New York, United States.

CDx Diagnostics is a funded company, having raised a total of $16.04M across 2 funding rounds to date. The company's 1st funding round was a Series A of $11.04M, raised on Dec 2019.

CDx Diagnostics was founded in 1997 and is headquartered in Suffern, United States. The company operates in the healthcare diagnostics sector, focusing on AI-driven technologies for early detection of precancerous conditions. Proprietary WATS3D biopsy platform is employed to identify tissue changes. Key products include OralCDx, a non-invasive oral brush biopsy system, and EndoCDx, a transepithelial laryngeal brush biopsy tool, supporting clinical assessments in oncology-related fields.

CDx Diagnostics's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.

CDx Diagnostics offers WATS 3D, OralCDx, and EndoCDx.

CDx Diagnostics has 1 investor. Key investors include Galen Partners.

Yes. CDx Diagnostics was acquired by Galen Partners in July 2017.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available